Icade SA Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/15/2026)
| Balance Sheet | Total Assets | 9,562,500,000.00 | ROE | 40.55 % |
| Balance Sheet | Total Equity | 3,877,300,000.00 | ROA | -1.29 % |
| Cashflow | Capital Expenditures | -305,500,000.00 | P/FCF | -220.04 |
| Cashflow | Free Cash Flow | -5,100,000.00 | – | – |
| Cashflow | Operating Cash Flow | 300,400,000.00 | P/CF | 3.74 |
| Income | Earnings per Share (diluted) | -1.62 | Div. Yield | 12.97 % |
| Income | Net Income | -123,000,000.00 | P/E | -9.14 |
| Income | Shares Outstanding | 75,826,100.00 | P/B | 0.29 |
| Income | Total Revenue | 1,449,600,000.00 | P/S | 0.77 |
Ratios calculated on: 10/14/2026
Company Description
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.icadmed.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more